Tyr319

Site Information
DDEKEDIyVNYPTFs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454845

In vivo Characterization
Methods used to characterize site in vivo:	flow cytometry ( 2 ) , immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Disease tissue studied:	leukemia ( 1 ) , T cell leukemia ( 1 ) , melanoma skin cancer ( 1 ) , cancer, squamous cell carcinoma ( 1 )
Relevant cell line - cell type - tissue:	B16F10 ( 1 ) , CHO (fibroblast) ( 1 ) , Hepa 1-6 (epithelial) ( 1 ) , HNSCC ( 1 ) , Jurkat (T lymphocyte) ( 1 ) , lymphocyte-spleen ( 2 ) , T lymphocyte ( 1 ) , YTS ( 2 )

Downstream Regulation
Effects of modification on DNAM-1:	molecular association, regulation ( 1 , 2 ) , protein degradation ( 1 ) , receptor internalization, induced ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cytoskeletal reorganization ( 2 )
Induce interaction with:	Cbl-b (human) ( 1 ) , GRB2 (mouse) ( 2 ) , PIK3R1 (mouse) ( 2 ) , VAV1 (mouse) ( 2 )

References
1	Braun M, et al. (2020) CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. Immunity 53, 805-823.e15 33053330 Curated Info
2	Zhang Z, et al. (2015) DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med 212, 2165-82 26552706 Curated Info